Cost–effectiveness of insulin detemir: a systematic review

References

• American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care31(3), 596–615 (2008). Erratum in: Diabetes Care31(6), 1271 (2008).
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care32(1), 193–203 (2009).
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on Type 2 diabetes mellitus: an algorithm for glycemic control. Endocr. Pract.15(6), 540–559 (2009). Erratum in: Endocr. Pract.15(7), 768–770 (2009).
   PubMed Web of Science ®Google Scholar
• Raslova K. An update on the treatment of Type 1 and Type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog. Vasc. Health Risk Manag.6, 399–410 (2010).
   PubMedGoogle Scholar
• Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with Type I diabetes mellitus using a basal-bolus regimen. Clin. Ther.26(5), 724–736 (2004).
   PubMed Web of Science ®Google Scholar
• Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall M-A. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulin (NPH insulin and regular human insulin) in basal bolus therapy for patients with Type 1 diabetes. Diabetologia47, 622–629 (2004).
   PubMed Web of Science ®Google Scholar
• Kolendorf K, Ross GP, Pavlic-Renar I et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabet. Med.23(7), 729–735 (2006).
   PubMed Web of Science ®Google Scholar
• Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet. Med.22(7), 850–857 (2005).
   PubMed Web of Science ®Google Scholar
• Home P, Bartley P, Russell-Jones D et al.; Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with Type 1 diabetes: a randomized clinical trial. Diabetes Care27(5), 1081–1087 (2004).
   PubMed Web of Science ®Google Scholar
• Pieber TR, Treichel H-C, Hompesch B et al. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet. Med.24(6), 635–642 (2007).
   PubMed Web of Science ®Google Scholar
• Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall M-A, Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet. Med.24, 27–34 (2006).
   Google Scholar
• Raslova K, Bogoev M, Raz I, Leth G, Gall M-A, Hancu M. Insulin detemir and insulin aspart: a promising basal-bolus regimen for Type 2 diabetes. Diabetes Res. Clin. Pract.66(2), 193–201 (2004).
   PubMed Web of Science ®Google Scholar
• Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose lowering drugs in insulin-naive people with Type 2 diabetes. Diabetes Care29(6), 1269–1274 (2006).
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled Type 2 diabetes. Clin. Ther.28(10), 1569–1581 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with Type 2 diabetes. Diabetologia51(3), 408–416 (2008).
   PubMed Web of Science ®Google Scholar
• Hollander P, Cooper J, Bregnhøj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with Type 2 diabetes. Clin. Ther.30(11), 1976–1987 (2008).
   PubMed Web of Science ®Google Scholar
• Raskin P, Gylvin T, Weng W, Chaykin L. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with Type 2 diabetes. Diabetes Metab. Res. Rev.25(6), 542–548 (2009).
   PubMed Web of Science ®Google Scholar
• Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared with neutral protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet. Med.25(4), 442–449 (2008).
   PubMed Web of Science ®Google Scholar
• Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost–effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care33(8), 1872–1894 (2010).
   PubMed Web of Science ®Google Scholar
• Bottomley JM, Raymond FD. Pharmaco-economic issues for diabetes therapy. Best Pract. Res. Clin. Endocrinol. Metab.21(4), 657–685 (2007).
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). Royal College of Physicians, London, UK (2008).
   Google Scholar
• WHO Commission on Macroeconomics and Health. Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. World Health Organization, Geneva, Switzerland (2001).
   Google Scholar
• Guillermin AL, Samyshkin Y, Wright D, Nguyen T, Villeneuve J. Modeling the lifetime costs of insulin glargine and insulin detemir in Type 1 and Type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis. J. Med. Econ.14(2), 207–216 (2011).
   PubMedGoogle Scholar
• Bierwirth RA, Kohlmann T, Moock J, Holle R, Landgraf W. [Costs of diabetes care and treatment satisfaction in Type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study]. Med. Klin. (Munich)105(11), 792–801 (2010).
   PubMedGoogle Scholar
• Pscherer S, Dietrich ES, Dippel FW, Neilson AR. Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in Type 2 diabetes in Germany. Ger. Med. Sci.8, pii: Doc 17 (2010).
   Google Scholar
• Valentine WJ, Aagren M, Haglund M, Ericsson A, Gschwend MH. Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with Type 1 diabetes using a basal-bolus regimen in Sweden. Scand. J. Public Health39(1), 79–87 (2011).
   PubMed Web of Science ®Google Scholar
• Waugh N, Cummins E, Royle P et al. Newer agents for blood glucose control in Type 2 diabetes: systematic review and economic evaluation. Health Technol. Assess.14(36), 1–248 (2010).
   Google Scholar
• Gundgaard J, Christensen TE, Thomsen TL. Direct healthcare costs of patients with Type 2 diabetes using long-acting insulin analogues or NPH insulin in a basal insulin-only regimen. Prim. Care Diabetes4(3), 165–172 (2010).
   PubMedGoogle Scholar
• Pscherer S, Dietrich ES, Dippel FW, Neilson AR. Comparison of one-year costs of Type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany. Int. J. Clin. Pharmacol. Ther.48(2), 129–137 (2010). Erratum in: Int. J. Clin. Pharmacol. Ther.48(4), 296 (2010).
   PubMedGoogle Scholar
• McAdam-Marx C, Yu J, Bouchard J, Aagren M, Brixner DI. Comparison of daily insulin dose and other antidiabetic medications usage for Type 2 diabetes patients treated with an analog basal insulin. Curr. Med. Res. Opin.26(1), 191–201 (2010).
   PubMed Web of Science ®Google Scholar
• Gschwend MH, Aagren M, Valentine WJ. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with Type 1 diabetes using a basal-bolus regimen in five European countries. J. Med. Econ.12(2), 114–123 (2009).
   PubMedGoogle Scholar
• Borah BJ, Darkow T, Bouchard J, Aagren M, Forma F, Alemayehu B. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with Type 2 diabetes. Clin. Ther.31(3), 623–631 (2009).
   PubMed Web of Science ®Google Scholar
• Tunis SL, Minshall ME, Conner C et al. Cost-effectiveness of insulin detemir compared with NPH insulin for Type 1 and Type 2 diabetes mellitus in the Canadian payer setting: modeling analysis. Curr. Med. Res. Opin.25(5), 1273–1284 (2009).
   PubMed Web of Science ®Google Scholar
• Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ180(4), 400–407 (2009).
   PubMed Web of Science ®Google Scholar
• [No authors listed]. [Insulin therapy in Type 2 diabetes. Insured patients would be willing to pay for added benefits]. MMW. Fortschr. Med.150(49–50), 56–57 (2008).
   Google Scholar
• Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin. Med. Res.6(2), 54–67 (2008).
   PubMedGoogle Scholar
• Valentine WJ, Goodall G, Aagren M, Nielsen S, Palmer AJ, Erny-Albrecht K. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with Type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. Adv. Ther.25(6), 567–584 (2008).
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Lammert M, Hermansen K. [Health economic consequences of insulin analogues in the treatment of Type 1 diabetes in Denmark]. Ugeskr. Laeger.170(15), 1250–1254 (2008).
   PubMedGoogle Scholar
• Leichter S. Is the use of insulin analogues cost-effective? Adv. Ther.25(4), 285–299 (2008).
   PubMed Web of Science ®Google Scholar
• Ilag LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of Type 2 diabetes: an evidence-based comparison. Clin. Ther.29(6 Pt 1), 1254–1270 (2007).
   Web of Science ®Google Scholar
• Morales J. Defining the role of insulin detemir in Basal insulin therapy. Drugs67(17), 2557–2584 (2007).
   PubMed Web of Science ®Google Scholar
• Russell-Jones DL. Insulin detemir and basal insulin therapy. Endocrinol. Metab. Clin. North Am.36(Suppl. 1), 7–13 (2007).
   PubMedGoogle Scholar
• Freemantle N, Stella P, Munro V. Comment and reply on: Relative efficacy/effectiveness and relative costs of treatment with insulin glargine and insulin detemir. Curr. Med. Res. Opin.23(8), 1761–1762; author reply 1762–1764 (2007).
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Erny-Albrecht KM, Ray JA, Roze S, Cobden D, Palmer AJ. Therapy conversion to insulin detemir among patients with Type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States. Adv. Ther.24(2), 273–290 (2007).
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Valentine WJ, Ray JA et al. An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with Type 1 diabetes in the UK. Curr. Med. Res. Opin.23(4), 895–901 (2007).
   PubMed Web of Science ®Google Scholar
• Sicat BL, Morgan LA. New therapeutic options for the management of diabetes. Consult. Pharm.22(1), 45–56 (2007).
   PubMedGoogle Scholar
• Jones MC, Patel M. Insulin detemir: a long-acting insulin product. Am. J. Health Syst. Pharm.63(24), 2466–2472 (2006). Erratum in: Am. J. Health Syst. Pharm.64(4), 346 (2007).
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Palmer AJ, Erny-Albrecht KM et al. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. Adv. Ther.23(2), 191–207 (2006).
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, Smith I, Wittrup-Jensen KU. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for Type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. Curr. Med. Res. Opin.20(11), 1729–1746 (2004).
   PubMed Web of Science ®Google Scholar
• Poole CD, Tetlow T, McEwan P, Holmes P, Currie CJ. The prescription cost of managing people with Type 1 and Type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr. Med. Res. Opin.23(S1), S41–S48 (2007).
   Web of Science ®Google Scholar
• Heintjes EM, Thomsen TL, Penning-van Beest FJ, Christensen TE, Herings RM. Glycemic control and long-acting insulin analog utilization in patients with Type 2 diabetes. Adv. Ther.27(4), 211–222 (2010).
   PubMed Web of Science ®Google Scholar
• Kabadi UM. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with Type 1 diabetes mellitus. Clin. Drug Investig.28(11), 697–701 (2008).
   PubMedGoogle Scholar
• Palmer AJ, Roze S, Valentine WJ et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision-making. Curr. Med. Res. Opin.20(Suppl. 1), S5–S26 (2004).
   PubMed Web of Science ®Google Scholar
• Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ180, 385–397 (2009).
   PubMed Web of Science ®Google Scholar
• Pieber TR, Plank J, Goerzer E. Duration of action, pharmacodynamic profile and between-subject variability of insulin detemir in subjects with Type 1 diabetes. Diabetes51(Suppl. 2), A53 (2004).
   Google Scholar
• Pieber TR, Treichel H-C, Robertson LI, Mordhorst L, Gall M-A. Insulin detemir plus insulin aspart is associated with less risk of major as well as nocturnal hypoglycaemia than insulin glargine plus insulin aspart at comparable levels of glycaemic control in Type 1 diabetes [abstract]. Diabetologia48(Suppl. 1), A92 (2005).
   Google Scholar
• Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with Type 1 diabetes: a 52-week, multinational, randomized, open label, parallel-group, treat-to-target noninferiority trial. Clin. Ther.31, 2086–2097 (2009).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with Type 2 diabetes. Diabetologia51, 408–416 (2007).
   Google Scholar
• Swinnen SG, Dain MP, Aronson R et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with Type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care33, 1176–1178 (2010).
   PubMed Web of Science ®Google Scholar
• Graf von der Schulenburg JM, Greiner W, Jost F et al.; Hanover Consensus Group. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health11(4), 539–544 (2008).
   PubMedGoogle Scholar
• Schulenburg JM, Greiner W, Jost F et al. German recommendations on health economic evaluation – third and updated version of the Hanover Consensus. Gersundhökon Qual. Manag.12, 285–290 (2007).
   Google Scholar
• Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with Type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes. Metab.9(3), 418–427 (2007).
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med.329(14), 977–986 (1993).
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. BMJ321(7258), 405–412 (2000).
   PubMed Web of Science ®Google Scholar
• Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int. J. Obes. Relat. Metab. Disord.26(Suppl. 3), S18–S24 (2002).
   PubMed Web of Science ®Google Scholar
• Ray KK, Seshasai SR, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet373(9677), 1765–1772 (2009).
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr. Med. Res. Opin.22(8), 1523–1534 (2006).
   PubMed Web of Science ®Google Scholar
• Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ. Couns.68(1), 10–15 (2007).
   PubMed Web of Science ®Google Scholar
• Le Floch JP, Lévy M, Mosnier-Pudar H et al.; Assessment of Detemir Administration in Progressive Treat-to-Target Trial (ADAPT) Study Group. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for Type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care32(1), 32–37 (2009).
   PubMed Web of Science ®Google Scholar
• Dornhorst A, Lüddeke HJ, Sreenan S et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from Type 1 and Type 2 diabetes patients in the PREDICTIVE European cohort. Int. J. Clin. Pract.61, 523–528 (2007).
   PubMed Web of Science ®Google Scholar
• Fontaine P, Gin H, Pinget M et al. Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE. Adv. Ther.26(5), 535–551 (2009).
   PubMed Web of Science ®Google Scholar
• Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes. Metab.9(5), 648–659 (2007).
   PubMed Web of Science ®Google Scholar
• Simon AC, Devries JH. The future of basal insulin supplementation. Diabetes Technol. Ther.13(S1), S103–S108 (2011).
   PubMed Web of Science ®Google Scholar